Grifols S.A. ADR Stock
Grifols S.A. ADR Stock
There is an upward development for Grifols S.A. ADR compared to yesterday, with an increase of €0.15 (1.900%).
Pros and Cons of Grifols S.A. ADR in the next few years
Pros
?
G***** c******* t* c**********
?
B****
?
C******** o* t** e**********
Cons
?
S********** s********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Grifols S.A. ADR vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Grifols S.A. ADR | 1.900% | 4.636% | 28.455% | -10.734% | -14.595% | -34.505% | -55.742% |
Cellectar BioSciences Inc. | -0.520% | 0.000% | 5.525% | -1.036% | -16.228% | -77.529% | - |
Beximco Pharmaceuticals Ltd. GDR | - | 0.000% | -39.000% | -41.905% | -44.545% | -77.615% | -39.604% |
SELLAS Life Sciences Group Inc | -1.760% | 3.894% | 7.313% | -16.973% | 20.410% | -86.956% | -80.864% |
Comments
Grifols, S.A. (NASDAQ: GRFS) was downgraded by analysts at Deutsche Bank Aktiengesellschaft from a "hold" rating to a "sell" rating.
Show more
Ratings data for GRFS provided by MarketBeat